Medical Castration using the Investigational Oral GnRH antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.

TAK-385 is a highly-selective, oral, non-peptide gonadotropin-releasing hormone antagonist being investigated as a possible prostate cancer treatment.

Evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-385 on luteinizing hormone and testosterone.

A three-part, randomized, double-blind, placebo-controlled, phase 1 dose-escalation study in 176 healthy male UK volunteers.

Part 1, single doses of TAK-385 (0 [placebo], 80, 120, 180, or 360 mg); Part 2, 14-day TAK-385 (40, 80, or 180 mg) daily; Part 3, 28-day TAK-385 or placebo (40 [with loading dose], 60, 80, or 160 mg) daily. Parts 2 and 3 included men aged 40-70 years.

Plasma concentrations of TAK-385, luteinizing hormone, and testosterone.

Oral TAK-385 was readily absorbed, and steady-state was reached in ≤14 days. Food reduced TAK-385 systemic exposure by 47%-52%. Mean serum testosterone levels declined ≤6 hours after TAK-385 administration. Loading doses up to 360 mg day 1, or 360 mg day 1 followed by 240 mg day 2 reduced the time to achieve castrate testosterone levels from ≥7 to 4 ng/mL. Following discontinuation of TAK-385 on day 28, testosterone levels normalized in most subjects in ≤28 days. Common adverse events included bradycardia, headache, and hot flush (all grade ≤2).

Oral TAK-385 (40-180 mg/day) was well tolerated and effectively lowered testosterone in healthy men. Planned phase 2 doses in men with hormone sensitive prostate cancer are 80 and 120 mg/day.

The Journal of clinical endocrinology and metabolism. 2015 Oct 26 [Epub ahead of print]

David B MacLean, Hongliang Shi, Helene Faessel, Fred Saad

Millennium Pharmaceuticals, Inc. , Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. , Millennium Pharmaceuticals, Inc. , Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. , Millennium Pharmaceuticals, Inc. , Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. , Millennium Pharmaceuticals, Inc. , Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe